Patent: 7,378,426
✉ Email this page to a colleague
Summary for Patent: 7,378,426
Title: | Fused heterotricyclic compounds as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 3 |
Abstract: | Disclosed are fused heterotricyclic compounds of the following formula I, ##STR00001## or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 3 (17.beta.-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds. |
Inventor(s): | Gavai; Ashvinikumar V. (Princeton Junction, NJ), Norris; Derek J. (Pennington, NJ), Han; Wen-Ching (Newtown, PA), Vite; Gregory D. (Titusville, NJ), Fink; Brian E. (West Windsor, NJ), Tokarski; John S. (Princeton, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/066,407 |
Patent Claims: | see list of patent claims |
Details for Patent 7,378,426
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Microbix Biosystems Inc. | KINLYTIC | urokinase | For Injection | 021846 | 01/16/1978 | ⤷ Try a Trial | 2024-03-01 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2024-03-01 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2024-03-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |